| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Endocrinology Unit, Department of Internal Medicine and Gastroenterologyand C.R.B.A., S. Orsola-Malpighi Hospital, 40138 Bologna, Italy (U.P., R.P.); Department of Physiological Chemistry, Johannes Gutenberg-University Mainz, Duesbergweg 6, 55099 Mainz, Germany (G.M., B.L.); University of Cincinnati, Department of Psychiatry, Obesity Research Center, Genome Research Institute, 2170 East Galbraith Road, Cincinnati, OH 45237, USA (D.C.)
* To whom correspondence should be addressed. E-mail: pagube{at}med.unibo.it.
During the last few years, the endocannabinoid system has emerged as a highly relevant topic in the scientific community. Many different regulatory actions have been attributed to endocannabinoids, and their involvement in several pathophysiological conditions is under intense scrutiny. Cannabinoid receptors, named CB1 receptor and CB2 receptor, first discovered as the molecular targets of the psychotropic component of the plant Cannabis sativa, participate in the physiological modulation of many central and peripheral functions. CB2 receptor is mainly expressed in immune cells, whereas CB1 receptor is the most abundant G protein-coupled receptor expressed in the brain. CB1 receptor is expressed in the hypothalamus and the pituitary gland, and its activation is known to modulate all the endocrine hypothalamic-peripheral endocrine axes. An increasing amount of data highlights the role of the system in the stress response by influencing the hypothalamic-pituitary-adrenal axis and in the control of reproduction by modifying gonadotropin release, fertility and sexual behavior.
The ability of the endocannabinoid system to control appetite, food intake and energy balance has recently received great attention, particularly in the light of the different modes of action underlying these functions. The endocannabinoid system modulates rewarding properties of food by acting at specific mesolimbic areas in the brain. In the hypothalamus, CB1 receptor and endocannabinoids are integrated components of the networks controlling appetite and food intake. Interestingly, the endocannabinoid system was recently shown to control metabolic functions by acting on peripheral tissues, such as adipocytes, hepatocytes, the gastrointestinal tract and, possibly, skeletal muscle. The relevance of the system is further strenghtened by the notion that drugs interfering with the activity of the endocannabinoid system are considered as promising candidates for the treatment of various diseases, including obesity.
This article has been cited by other articles:
 |
|
 |
|
  L. Tedesco, A. Valerio, C. Cervino, A. Cardile, C. Pagano, R. Vettor, R. Pasquali, M. O. Carruba, G. Marsicano, B. Lutz, et al. Cannabinoid Type 1 Receptor Blockade Promotes Mitochondrial Biogenesis Through Endothelial Nitric Oxide Synthase Expression in White Adipocytes Diabetes, August 1, 2008; 57(8): 2028 - 2036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. W. Wu, A. Tajar, S. R. Pye, A. J. Silman, J. D. Finn, T. W. O'Neill, G. Bartfai, F. Casanueva, G. Forti, A. Giwercman, et al. Hypothalamic-Pituitary-Testicular Axis Disruptions in Older Men Are Differentially Linked to Age and Modifiable Risk Factors: The European Male Aging Study J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2737 - 2745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bifulco, A. M. Malfitano, S. Pisanti, and C. Laezza Endocannabinoids in endocrine and related tumours Endocr. Relat. Cancer, June 1, 2008; 15(2): 391 - 408. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Eckel Nonsurgical Management of Obesity in Adults N. Engl. J. Med., May 1, 2008; 358(18): 1941 - 1950. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Kunos and D. Osei-Hyiaman Endocannabinoids and Liver Disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis Am J Physiol Gastrointest Liver Physiol, May 1, 2008; 294(5): G1101 - G1104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Andrikopoulos and S. Tzeis Modification of Cardiometabolic Risk Through Cannabinoid Type-1 Receptor Antagonism Angiology, April 1, 2008; 59(2_suppl): 44S - 48S. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Paradisi, N. Pasquariello, D. Barcaroli, and M. Maccarrone Anandamide Regulates Keratinocyte Differentiation by Inducing DNA Methylation in a CB1 Receptor-dependent Manner J. Biol. Chem., March 7, 2008; 283(10): 6005 - 6012. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Nesto and K. Mackie Endocannabinoid system and its implications for obesity and cardiometabolic risk Eur. Heart J. Suppl., March 1, 2008; 10(suppl_B): B34 - B41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Van Gaal, X. Pi-Sunyer, J.-P. Despres, C. McCarthy, and A. Scheen Efficacy and Safety of Rimonabant for Improvement of Multiple Cardiometabolic Risk Factors in Overweight/Obese Patients: Pooled 1-year data from the Rimonabant in Obesity (RIO) program Diabetes Care, February 1, 2008; 31(Supplement_2): S229 - S240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pagano, C. Pilon, A. Calcagno, R. Urbanet, M. Rossato, G. Milan, K. Bianchi, R. Rizzuto, P. Bernante, G. Federspil, et al. The Endogenous Cannabinoid System Stimulates Glucose Uptake in Human Fat Cells via Phosphatidylinositol 3-Kinase and Calcium-Dependent Mechanisms J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4810 - 4819. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Roberge, A. C. Carpentier, M.-F. Langlois, J.-P. Baillargeon, J.-L. Ardilouze, P. Maheux, and N. Gallo-Payet Adrenocortical dysregulation as a major player in insulin resistance and onset of obesity Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1465 - E1478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Bray and F. L. Greenway Pharmacological Treatment of the Overweight Patient Pharmacol. Rev., June 1, 2007; 59(2): 151 - 184. [Full Text] [PDF]
|
|
|
|
|
|
P. Russo, P. Strazzullo, F. P. Cappuccio, D. A. Tregouet, F. Lauria, M. Loguercio, G. Barba, M. Versiero, and A. Siani Genetic Variations at the Endocannabinoid Type 1 Receptor Gene (CNR1) Are Associated with Obesity Phenotypes in Men J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2382 - 2386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cota, M.-A. Steiner, G. Marsicano, C. Cervino, J. P. Herman, Y. Grubler, J. Stalla, R. Pasquali, B. Lutz, G. K. Stalla, et al. Requirement of Cannabinoid Receptor Type 1 for the Basal Modulation of Hypothalamic-Pituitary-Adrenal Axis Function Endocrinology, April 1, 2007; 148(4): 1574 - 1581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Denver Endocannabinoids Link Rapid, Membrane-Mediated Corticosteroid Actions to Behavior Endocrinology, February 1, 2007; 148(2): 490 - 492. [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Foster-Schubert and D. E. Cummings Emerging Therapeutic Strategies for Obesity Endocr. Rev., December 1, 2006; 27(7): 779 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. KYROU, G. VALSAMAKIS, and C. TSIGOS The Endocannabinoid System as a Target for the Treatment of Visceral Obesity and Metabolic Syndrome Ann. N.Y. Acad. Sci., November 1, 2006; 1083(1): 270 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Bluher, S. Engeli, N. Kloting, J. Berndt, M. Fasshauer, S. Batkai, P. Pacher, M. R. Schon, J. Jordan, and M. Stumvoll Dysregulation of the Peripheral and Adipose Tissue Endocannabinoid System in Human Abdominal Obesity Diabetes, November 1, 2006; 55(11): 3053 - 3060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Pacher, S. Batkai, and G. Kunos The Endocannabinoid System as an Emerging Target of Pharmacotherapy Pharmacol. Rev., September 1, 2006; 58(3): 389 - 462. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
